News - Grey Wolf Therapeutics

£1.1m InnovateUK grant funding to accelerate ERAP1 inhibitor programme

May 18, 2021

Grey Wolf Therapeutics will collaborate with The University of Oxford and the University of Southampton to accelerate and expand the therapeutic potential of ERAP1 inhibition...

£2.5m Series A2 financing for development of therapies targeting ERAP2

January 9, 2020

Grey Wolf Therapeutics, a drug discovery biotechnology company focused on developing first-in-class therapies for immuno-oncology (IO), today announces it has completed a £2.5 million ($3.3 million) Series A2 financing round...

GWT completes £10m ($14m) series A financing

February 11, 2019

Grey Wolf Therapeutics, a drug discovery biotechnology company focused on immuno-oncology, today announces it has completed a £10 million ($14 million) series A financing round with leading international healthcare investors...

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
_GRECAPTCHA	6 months	Google Recaptcha service sets this cookie to identify bots to protect the website against malicious spam attacks.
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie records the user consent for the cookies in the "Advertisement" category.
cookielawinfo-checkbox-analytics	1 year	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	1 year	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	1 year	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	1 year	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	1 year	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
rc::a	session	This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.
rc::b	session	This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.
rc::c	session	This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.
rc::f	session	This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.
viewed_cookie_policy	1 year	This cookie is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
wordpress_[hash] (Admin only)	session	Used to store the authentication details on login. The authentication details include the username and double hashed copy of the password. However, this usage of the cookie is limited to the admin console area, the backend dashboard of the website.
wordpress_logged_in_XXX	session	WordPress uses this cookie to indicate when you’re logged in, and who you are, for most interface use.

Functional

Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

Cookie	Duration	Description
-settings-1, wp-settings-time-1	1 year	WordPress uses this cookie to customize your view of admin interface, and possibly also the main site interface.

Performance

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

Cookie	Duration	Description
_ga	1 year 1 month 4 days	Google Analytics sets this cookie to calculate visitor, session and campaign data and track site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognise unique visitors.
_ga_*	1 year 1 month 4 days	Google Analytics sets this cookie to store and count page views.

Others

Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

Cookie	Duration	Description
cerber_groove cerber_groove_x_#	14 days	Protect the website from hackers, cyber criminals, spammers.

Latest news

£1.1m InnovateUK grant funding to accelerate ERAP1 inhibitor programme

£2.5m Series A2 financing for development of therapies targeting ERAP2

GWT completes £10m ($14m) series A financing

RECENT FROM

Announcing the appointment of our new Chief Medical Officer, Tom Lillie!

Biopharma Exec Brett Carter appointed to Board of Directors of Australian Subsidiary

Appointment of Cassian Yee to Clinical Advisory Board

Latest news

£1.1m InnovateUK grant funding to accelerate ERAP1 inhibitor programme

£2.5m Series A2 financing for development of therapies targeting ERAP2

GWT completes £10m ($14m) series A financing

RECENT FROM

Announcing the appointment of our new Chief Medical Officer, Tom Lillie!

Biopharma Exec Brett Carter appointed to Board of Directors of Australian Subsidiary

Appointment of Cassian Yee to Clinical Advisory Board

Cookies